TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00547105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
Study: NCT02337205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment
Description: KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
Study: NCT03528928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation
Description: Thin electrode with four conductive areas placed over the perineal area.
Study: NCT03954496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive upper extremity motor training
Description: This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive upper extremity motor training
Description: This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
Study: NCT02698254

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy with conventional fractionation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy with conventional fractionation
Study: NCT01496508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation (SLE 5000, Servo-i-Maquet)
Description: Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation (SLE 5000, Servo-i-Maquet)
Description: Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
Study: NCT03315819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart repair
Description: Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization interne rotation
Description: Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
Study: NCT01674257

Intervention type: OTHER
Intervention: USPIO (ferumoxytol)-enhanced MRI scan
Description: Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.

Intervention type: RADIATION
Intervention: 18f-Fluoride PET/CT scan

Intervention type: RADIATION
Intervention: 18F-Flurodeoxyglucose PET/CT scan
Study: NCT02262260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labeled regime arm
Description: Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wait and Extend regime arm
Description: Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
Study: NCT01218867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
Study: NCT02806284

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23, Act-HIB
Description: described in Arm description

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23, Act-HIB
Description: described in Arm description

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23, Act-HIB
Description: described in Arm description
Study: NCT01799772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention
Description: 1. Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~2. Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~3. Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~4. Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Exercise Program
Description: Typical rehabilitation after TKA surgery
Study: NCT00650923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01069848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vedera KXS
Description: One treatment session with Vedera KXS
Study: NCT00872066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartSet® HV bone cement
Description: A high viscosity bone cement for use in total hip replacement (without gentamicin)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartSet® GHV bone cement
Description: A high viscosity bone cement for use in total hip replacement (with gentamicin)
Study: NCT02489370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Description: The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
Study: NCT03733652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa 2a
Description: Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
Study: NCT02024776

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: Tailored exercise training program
Study: NCT03794986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma-informed SGM affirmative care
Description: All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use).
Study: NCT01218867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
Study: NCT02075190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Computerized intervention
Description: Remediation training intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nontherapeutic computerized intervention
Description: Online gaming intervention
Study: NCT00884520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] VM4-037
Description: The individual doses of \[F-18\]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging.
Study: NCT04013399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
Study: NCT02566408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-on-one interview
Description: Undergo one-on-one interview about KAPs towards PA
Study: NCT02908854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adding spices and herbs to school lunch vegetables
Description: Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
Study: NCT03794986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda
Study: NCT02566408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Questions
Description: Complete survey
Study: NCT04042935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
Study: NCT03768557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline (200mg)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Lactose (400mg)
Study: NCT02763592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo plaster
Description: This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
Study: NCT00495079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo® (vincristine sulfate liposomes injection)
Description: Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
Study: NCT02940106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotop device
Description: a different device for oocyte vitrification (with a very high cooling rate)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CBSvit device
Description: a different device for oocyte vitrification (with a lower cooling rate)
Study: NCT02927405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: anticonvulsant drug that is used for neuropathic pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: a procedure done anesthetize the anterior abdominal wall

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAP Block
Description: a procedure done anesthetize the anterior abdominal wall
Study: NCT01380938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a + Ribavirin
Description: Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a + Ribavirin
Description: Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight \< or \> 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)
Study: NCT03705936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
Study: NCT02573701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline treatment (Risperidone, administered orally)
Description: Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (any other antipsychotic)
Description: Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
Study: NCT02523612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT04549974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat exposure
Description: Participants will be exposed to heat exposure via a water-perfused suit to increase internal body temperature by 1.5 degrees Celsius.
Study: NCT01423604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching ruxolitinib
Study: NCT00424255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Dual ErbB1/2 inhibitor

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Chemoradiation
Description: Radiation plus platinum based chemotherapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01501045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS system MagPro x100, Tonica Elektronik A/S, Denmark
Description: repeated TMS (rTMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS system MagPro x100, Tonica Elektronik A/S, Denmark
Description: repeated TMS
Study: NCT03889483

Intervention type: DEVICE
Group type: OTHER
Intervention: NeuroCatch™ Platform
Description: The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study: NCT02095314

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentavalen
Description: Batch 5010613
Study: NCT00610636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: Hepatic resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic resection
Description: Hepatic resection
Study: NCT00472303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tapentadol Extended Release
Description: Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Extended Release
Description: Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo after Tapentadol in the Titration Phase.
Description: Tablet taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulphate Controlled Release
Description: Capsule taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.